Skip to content
Veracyte is a leading genomic diagnostics company that is fundamentally improving patient care by resolving diagnostic uncertainty with evidence that is trustworthy and actionable. The company’s products uniquely combine genomic technology, clinical science and machine learning to provide answers that give physicians and patients a clear path forward without risky, costly surgery that is often unnecessary.
Since its founding in 2008, Veracyte has commercialized three genomic tests, which are transforming the diagnosis of thyroid cancer, lung cancer and idiopathic pulmonary fibrosis and collectively target a $2 billion market opportunity. Veracyte is based in South San Francisco, California. Veracyte’s common stock is listed on The NASDAQ Global Market under the symbol VCYT.


Press Releases

Date Title and Summary Additional Formats
Toggle Summary Veracyte to Host Virtual Lung Cancer R&D Day on Wednesday, December 16, 2020
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Dec. 3, 2020-- Veracyte, Inc. (Nasdaq: VCYT), a global genomic diagnostics company, will host a Virtual Lung Cancer R&D Day for investors and analysts on December 16, 2020 , from 10:00 a.m. to 12:00 p.m. EST .
Toggle Summary Veracyte to Participate in Piper Sandler 32nd Annual Virtual Healthcare Conference
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Nov. 23, 2020-- Veracyte, Inc . (Nasdaq: VCYT), a global genomic diagnostics company, announced today that Bonnie Anderson , chairman and chief executive officer, will participate in a fireside chat and host one-on-one meetings at the Piper Sandler


Date Event Details
Summary Toggle Dec 16, 2020 10:00 AM EST


Title Documents

Corporate Presentation December 2020